Introduction {#s1}
============

Type 2 immunity is generated by the immune system in response to a range of environmental challenges from helminth worm parasites, ectoparasites and allergens ([@bib21]; [@bib23]). In the absence of any vaccines, gastrointestinal helminths continue to infect many hundreds of millions of people in less-affluent countries ([@bib49]). Type 2 immunity to parasites is critically dependent upon pathways driven through and co-ordinated by IL-4Rα signaling ([@bib63]; [@bib65]). IL-4Rα activation can result in a multitude of immune outcomes ([@bib1]; [@bib44]), however, few other components of immunity have been defined as either necessary or sufficient for worm expulsion.

The epithelial-derived 'alarmin' cytokines, including IL-25, IL-33 and TSLP elicit and amplify type 2 immunity through the action of group two innate lymphoid cells (ILC2s) ([@bib34]; [@bib37]; [@bib72]). There are however important distinctions in both the modes of action of these cytokines, and in the cells, bearing receptors for each mediator. Thus, ligation of the heterodimeric TSLP receptor stimulates dendritic cells to favor a Th2 cell response, and activates innate type 2 populations ([@bib28]; [@bib55]; [@bib57]; [@bib73]); IL-25 receptors (heterodimers of IL-17RA and IL-17RB chains) are expressed on a number of tissues and cell types and increase IL-4 expression by Th2 cells ([@bib2]); and receptors for IL-33 (an Interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2) are broadly expressed in many tissues and induce type 2 cytokine expression by ILC2s and T cells ([@bib8]; [@bib53]).

Although IL-25 (originally termed IL-17E) shares structural similarity with other IL-17 family members it acts in an opposing manner to IL-17A, by inducing a suite of Type 2 responses ([@bib32]; [@bib43]) and preventing IL-17A-dependent autoimmune disease ([@bib33]). IL-25 is highly expressed within the tuft cells of the gastrointestinal tract ([@bib15]; [@bib66]), but is also produced by a range of core immune populations, including T cells and granulocytes. IL-25 plays an important role in inducing allergic inflammation ([@bib6]; [@bib48]) and in driving tissue remodeling and fibrosis ([@bib18]; [@bib22]).

A number of laboratories have reported that IL-25 is induced by infection with, and required for immunity to, the nematode *Nippostrongylus brasiliensis*, a rat parasite that briefly infects immune-competent mice ([@bib12]; [@bib14]; [@bib27]; [@bib71]), as well as the nematodes *Heligmosomoides polygyrus ([@bib45])*, *Trichuris muris ([@bib42])* and *Trichinella spiralis* ([@bib3]). IL-25 may be more important in activation of innate than adaptive immunity, as IL-25-deficient mice mounted normal Th2 responses following *N. brasiliensis* infection ([@bib38]), while ILCs grown in vitro in the presence of IL-25 and IL-33 were able to stimulate expulsion of this parasite upon adoptive transfer to susceptible IL-25R-deficient (*Il17rb*^-/-^) mice ([@bib40]).

Due to the rapid nature of expulsion of *N. brasiliensis*, it is difficult to separate the role of IL-25 in the initial drive towards Th2 responsiveness and any subsequent activation of effector mechanisms. We therefore studied chronic infection with the nematode *H. polygyrus,* in which induction over the first 7--10 days can be analysed separately from the subsequent expulsion phase: in so doing, we report that IL-25 is in fact redundant for Th2 initiation, but acts during the later phase of effector expulsion against this helminth parasite. Such a downstream role is consistent with recent reports demonstrating a role for IL-25 in protective immunity to a secondary infection with *H. polygyrus*, following drug clearance of a primary infection ([@bib45]), or vaccination with parasite secreted antigens ([@bib25]). More broadly, a critical role for IL-25 in a late-stage immune response is also evident in airway inflammation models, in which it plays a central role in stimulating inflammatory myeloid cells and promoting airway remodeling ([@bib18]; [@bib47]), or in driving allergic reactions to airway challenge in previously sensitized mice ([@bib5]; [@bib8]).

Results {#s2}
=======

IL-25R is redundant for generation of adaptive type-2 responses following chronic helminth infection {#s2-1}
----------------------------------------------------------------------------------------------------

To investigate the role of IL-25R in generation of innate and adaptive type-2 responses following chronic parasite infection, we used mice deficient in the IL-25-specific receptor subunit *Il17rb ([@bib40])*. We evaluated the outcome of *H. polygyrus* infection in mice of the BALB/c genetic background, which are partially resistant and able to expel most adult worms by day 28 following infection ([@bib13]; [@bib50]). At day 14 post-infection, shortly after adult worms have matured, *Il17rb*^-/-^ mice exhibited significantly increased egg production ([Figure 1A](#fig1){ref-type="fig"}) but equivalent adult worm burdens ([Figure 1B](#fig1){ref-type="fig"}) to the IL-25-sufficient wild-type BALB/c. By day 28, the *Il17rb*^--/--^ genotype was unable to reduce adult worm or egg burdens ([Figure 1C,D](#fig1){ref-type="fig"}).

![IL-25R signaling is required for expulsion of *H.*\
*polygyrus* from BALB/c mice. *H. polygyrus*-infected BALB/c or *Il17rb*-deficient (IL25R^--/--^) BALB/c mice were analyzed at day 14 post-infection for fecal egg counts (**A**) and intestinal adult worm burden (**B**) or day 28 post-infection for fecal egg counts (**C**) and intestinal adult worm burden (**D**). MLN cells underwent intracellular cytokine staining (ICCS) to compare the number of Lin^-^ICOS^+^innate lymphoid cells (ILCs) (**E**) and IL-13^+^ ILC2s (**F**) by flow cytometry in the different naïve and day 14 infected genotypes. Peritoneal lavage cells (PL) were stained with Siglec-F, CD11b and Ly6G/C to compare the number of Siglec-F^-^CD11b^+^Ly6G/C^+^ monocytes (**G**) in the different naïve and day 14 infected genotypes. Percentages of eosinophils (**H**) and RELMα^+^ alternatively-activated macrophages (Ι) were also determined over a 4 week infection timecourse. ELISA of supernatants from MLN cells incubated with media or 1 μg HES for 72 hr was performed to compare IL-4 (**J**), IL-5 (**K**) and IL-13 (**L**) production in the different naïve and day 14 infected genotypes. ICCS of MLN allowed a comparison of the proportion of IL-4^+^, IL-5^+^ and IL-13^+^ CD4^+^ T cells by flow cytometry in the different naïve and day 14 infected genotypes (**M--O**). Results shown are one representative of three experiments with n ≥ 4 mice/group (**A--D**), pooled data from two experiments with n ≥ 4 mice/group (**C--F, M--O**) or one representative of two experiments with n ≥ 4 mice/group (**G--L**). Data were analysed by unpaired *t* test or one way ANOVA, where \*=p≤0.05,\*\*=p≤0.01,\*\*\*=p≤0.001 and ns = not significant. Error bars represent Standard Error of the Mean.](elife-38269-fig1){#fig1}

A number of cell types have been shown to express IL-25R and contribute to type-2 inflammation, including ILCs and multi-potent progenitor type-2 cells ([@bib26]; [@bib52]), myeloid cells ([@bib10]; [@bib47]), NKT cells ([@bib58]; [@bib61]) and eosinophils ([@bib32]). We first took the approach of analysing individual cell types within BALB/c and *Il17rb*^--/--^ mice and found equivalent increases in total and IL-13-expressing ILCs in the mesenteric lymph node (MLN, [Figure 1E,F](#fig1){ref-type="fig"}) in both strains at day 14 post-infection, and similar increases in the number of Siglec-F^-^CD11b^+^Ly6C/G^+^ myeloid cells in the peritoneal lavage (PL) ([Figure 1G](#fig1){ref-type="fig"}). However, we noted significantly reduced proportions of Siglec-F^+^ eosinophils and resistin-like molecule (RELM)-α^+^ macrophages in the PL of *Il17rb*^--/--^ mice at steady-state and during the acute phase of infection (day 7). From day 14 when parasites are in the intestinal lumen and infection enters chronicity, proportions of both cell types increased closer to levels found in wild-type mice ([Figure 1H,I](#fig1){ref-type="fig"}). We also evaluated typical type 2 cytokine production (IL-4, IL-5 and IL-13) in response to restimulation with parasite antigen (HES); this was found to be equivalent in *H.polygyrus*-infected BALB/c and *Il17rb*^--/--^ mice ([Figure 1J--L](#fig1){ref-type="fig"}). Intracellular cytokine staining of MLN CD4^+^ T cell populations showed no significant difference in expression of IL-4 ([Figure 1M](#fig1){ref-type="fig"}), IL-5 ([Figure 1N](#fig1){ref-type="fig"}) or IL-13 ([Figure 1O](#fig1){ref-type="fig"}) between *H.polygyrus*-infected BALB/c and *Il17rb*^--/--^ mice.

Effective clearance of adult worms requires IL-25R within the hematopoietic immune compartment {#s2-2}
----------------------------------------------------------------------------------------------

During inflammation, expression of IL-25R has also been reported on antigen presenting cells ([@bib17]), memory T cells ([@bib67]), eosinophils ([@bib60]) and human vascular endothelial cells ([@bib68]) as well as human fibroblasts ([@bib18]). In addition, intestinal smooth muscle hypercontractility is compromised in IL-25-deficient helminth-infected mice ([@bib45]). Thus, non-hematopoietic or hematopoietic cell expression of IL-25R might contribute to parasite expulsion in BALB/c mice. To assess this possibility, bone marrow chimeras were generated, infected with *H. polygyrus* and analysed 28 days later for egg and worm burden. Control chimeras reflected the phenotypes of intact mice as *Il17rb*^--/--^ reconstituted with *Il17rb*^--/--^ bone-marrow had significantly higher worm burdens than BALB/c reconstituted with BALB/c bone-marrow ([Figure 2A](#fig2){ref-type="fig"}). Efficient adult worm expulsion and decreased egg burden were evident in mice lacking IL-25R on the non-hematopoietic compartment (*Il17rb*^--/--^ reconstituted with BALB/c bone-marrow), however, delayed worm expulsion and increased egg burden occurred in mice lacking IL-25R within the hematopoietic immune compartment ([Figure 2A,B](#fig2){ref-type="fig"}).

![IL-25R signaling is required within the hematopoietic compartment for efficient expulsion.\
Bone marrow chimeras generated from BALB/c (WT) or *Il17rb*-deficient (KO) donor and BALB/c (WT) or *Il17rb*-deficient (KO) recipient mice were infected with *H. polygyrus* and intestinal adult worm burden (**A**) and fecal egg burden (**B**) performed at day 28 post-infection. Results shown are pooled data from two experiments performed with n ≥ 3 mice/group, and data from all individual mice are presented. Data were analysed by unpaired *t* test, where \*=p≤0.05,\*\*=p≤0.01,\*\*\*=p≤0.001 and ns = not significant. Error bars represent Standard Error of the Mean.](elife-38269-fig2){#fig2}

Effective clearance of adult worms in immune-deficient mice requires IL-25R and IL-4Rα signaling through the innate immune compartment {#s2-3}
--------------------------------------------------------------------------------------------------------------------------------------

To test whether stimulation of IL-25R within the innate immune compartment mediates adult worm expulsion and whether this is enhanced following IL-4Rα signaling, immune-deficient *Rag1*^-/-^ mice were infected with *H. polygyrus* and injected with recombinant IL-25 late in infection (d14-17) and/or a complex of rIL-4:anti-IL-4 (IL-4C) on days 13, 16 and 19 post-infection ([Figure 3A](#fig3){ref-type="fig"}). IL-4C exerted significant but modest reductions in egg counts (44%) and adult worm burden (34%) in *Rag1*^-/-^ mice but did not completely expel adult worms or eliminate egg production ([Figure 3B,C](#fig3){ref-type="fig"}). Administration of IL-25 alone to *Rag1*^-/-^ mice elicited a downward trend in adult worm numbers, which did not attain statistical significance in two experimental repeats. However when both cytokines were combined, egg production was reduced by 95% and the adult worm burden also greatly reduced (by 87%).

![IL-25R signaling synergises with IL-4Rα within the innate immune compartment to facilitate efficient worm expulsion.\
*H. polygyrus*-infected *Rag1^-/-^* mice (RAG*^-/-^*) were given 0.4 µg recombinant IL-25 i.p. days 14--17 (late) post-infection with or without a complex of 5 μg rIL-4 and 25 μg anti-IL-4 (IL-4C) on days 13, 16 and 19 post-infection, according the schedule shown in (**A**). Mice were analyzed at 28 days post-infection for fecal egg burden (**B**) and intestinal adult worm burden (**C**). *H. polygyrus*-infected *Rag1^-/-^* mice were given IL-25 and IL-4C according to the same schedule, as well as 200 µg of anti-CD90.2/Th1.2 antibody or rat IgG2b control (days 12, 15, 18 and 21). The peritoneal lavage was analyzed at 28 days post-infection for CD45^+^lin^-^ (CD3, CD5, CD8α, CD11c, CD19, DX5, F4/80, GR-1, TCRβ, CD11b), ICOS and ST2 staining by flow cytometry as shown (**D**) and the number of CD45^+^lin^--^ (**E**), CD45^+^lin^--^ST2^--^ (**F**) and CD45^+^lin^--^ST2^+^ (**G**) ILCs was determined. Mice were analysed at 28 days post-infection for fecal egg burden (**H**) and intestinal adult worm burden (**I**). Results shown are one representative of two experiments with n = 4 mice/group (**D--G**), or pooled data from two experiments with n ≥ 3 mice/group (**B,C,H,I**). Data were analysed by unpaired *t* test, where \*=p≤0.05,\*\*=p≤0.01,\*\*\*=p≤0.001 and ns = not significant. Error bars represent Standard Error of the Mean.](elife-38269-fig3){#fig3}

ILC2s may have a role in promoting acquired type-2 immune responses by activation of CD4^+^ T cell responses through expression of OX40L, MHC class II and PD-L1 ([@bib11]; [@bib39]; [@bib41]; [@bib54]) or by promoting dendritic cell migration to draining lymph nodes following IL-13 production ([@bib20]). Sustained activation of ILCs drives immunity to *N. brasiliensis* infection ([@bib7]), however in *H. polygyrus* infection the transfer of activated ILC2s had only a limited effect on worm establishment ([@bib46]). In addition, IL-25 is able to induce type 2 inflammation and goblet cell hyperplasia in the small intestine, independently of ILCs ([@bib52]). To test whether ILCs contribute to efficient worm expulsion in immune-compromised mice following co-administration of IL-25 and IL-4C, we treated *H. polygyrus* infected *Rag1*^-/-^ mice with both cytokines and isotype or anti-CD90.2 (Thy1.2) antibodies. Administration of anti-CD90.2 antibody significantly reduced the number of CD45^+^Lin^-^ ILCs ([Figure 3D,E](#fig3){ref-type="fig"}) as well as the number of CD45^+^Lin^-^ST2^-^ and CD45^+^Lin^-^ST2^+^ ILCs ([Figure 3F,G](#fig3){ref-type="fig"}) in the PL of *H. polygyrus*-infected *Rag1*^-/-^ mice treated with IL-25 and IL-4C. However, immunity was fully intact in recipients of this antibody, with significantly decreased parasite egg and worm burden in ILC-depleted mice ([Figure 3H,I](#fig3){ref-type="fig"}).

Stimulation of IL-25R induces adult worm clearance late, but not early, in infection {#s2-4}
------------------------------------------------------------------------------------

The late manifestation of the *Il17rb*^--/--^ phenotype in *H. polygyrus* infection could reflect a requirement either for initial IL-25 to generate an effector response that is only active after day 14, or for a later IL-25R-driven pathway that is invoked once the Th2 response is generated. To evaluate the relative importance of IL-25R engagement during different phases of infection, we made use of the more susceptible C57BL/6 strain and delivered exogenous rIL-25 early (day 1--4) and late (day 14--17) post-infection ([Figure 4A](#fig4){ref-type="fig"}). Egg counts were equivalent at day 14 post-infection before delivery of IL-25 late ([Figure 4B](#fig4){ref-type="fig"}) and were significantly reduced in recipients of IL-25 early (66%; p=0.0013) or late (64%; p=0.0071) compared to PBS controls by day 28 post-infection ([Figure 4C](#fig4){ref-type="fig"}). Although early IL-25 administration also induced a modest reduction in adult worm burdens, this did not reach significance in two repeated experiments. In contrast, adult worm burden was significantly reduced in recipients of IL-25 late (66%; p=0.0016) at day 28 post-infection ([Figure 4D](#fig4){ref-type="fig"}). Both CD4^+^ T cell IL-4 and IL-13 responses ([Figure 4E--F](#fig4){ref-type="fig"}), and the total number of ILCs ([Figure 4G](#fig4){ref-type="fig"}) were not significantly altered by late IL-25 injection. The number of IL-13^+^ILCs (ILC2s) was not significantly increased in the MLN at day 18 *hr. polygyrus* infection but was significantly increased in infected mice following the administration of IL-25 ([Figure 4H](#fig4){ref-type="fig"}), however, these remained a small proportion of the total ILCs within the MLN

![IL-25 induces protective immune responses in the late stage of infection.\
*H. polygyrus*-infected C57BL/6 mice were given 0.4 μg recombinant IL-25 i.p. at day 1--4 (early) or day 14--17 (late) post-infection according to the schedule shown in (**A**). Before administration of IL-25, intestinal egg burden was analysed in two groups at day 14 post-infection (**B**). Mice were then analysed at day 28 post-infection for fecal egg counts (**C**) and intestinal adult worm burden (**D**) following administration of IL-25 early or late. *H. polygyrus*-infected C57BL/6 mice were given 0.4 μg recombinant IL-25 i.p. at day 14--17 (late) post-infection. Day 18 post-infection, MLN cells underwent ICCS to compare the proportion of IL-4^+^CD4^+^ (**E**) and IL-13^+^CD4^+^ (**F**) T cells, as well as the number of ILCs (**G**) and Lin-IL-13 + ILC2 s (**H**) by flow cytometry. Results shown are data pooled from three experiments with n ≥ 3 mice/group (**B--D**), or are representative of two experiments with n = 4 mice/group (**E,F**) or pooled from two experiments with n = 4 mice/group (**G, H**). Data were analysed by unpaired *t* test, where \*=p≤0.05,\*\*=p≤0.01,\*\*\*=p≤0.001 and ns = not significant. Error bars represent Standard Error of the Mean.](elife-38269-fig4){#fig4}

Monocytes and eosinophils require IL-25R and IL-4Rα signaling for a maximal type-2 response {#s2-5}
-------------------------------------------------------------------------------------------

Monocytes are important regulators of wound repair following Th2 inflammation and are activated to proliferate within the tissue site in response to IL-4Rα signaling, as confirmed in *H. polygyrus*-infected mice ([@bib29]). These cells also respond to the alarmins IL-25 and IL-33 to promote type-2 cytokine production and alternative activation, where adoptive transfer of IL-33-activated macrophages has been reported to induce worm expulsion in mice with chronic *H. polygyrus* infection ([@bib69]). Eosinophils also respond to IL-25 and are thought to play a role in limiting Th2 responses following *H. polygyrus* infection ([@bib59]).

Analysis of the peritoneal lavage revealed striking changes within macrophage and eosinophil populations following administration of IL-25 to *H. polygyrus* infected mice. IL-25 injection significantly increased production of IL-13 by Siglec-F^+^CD11b^+^F4/80^+^ monocyte populations following administration of IL-25 to naïve and *H. polygyrus* infected mice ([Figure 5A,B](#fig5){ref-type="fig"}). Administration of IL-25 also significantly increased expression of the marker of alternative activation RELM-α by naïve macrophages in vivo (in an environment with low IL-4/13 levels), however alternative activation was further increased above and beyond this level in the setting of *H. polygyrus* infection ([Figure 5B,C](#fig5){ref-type="fig"}). A similar pattern was seen for the number of eosinophils in the PL ([Figure 5D,E](#fig5){ref-type="fig"}). The number of peritoneal monocytes was also significantly increased in response to IL-25, similar to the setting of *H. polygyrus* infection and a combination of infection and IL-25 ([Figure 5F](#fig5){ref-type="fig"}). In vitro treatment of bone-marrow-derived macrophages with recombinant cytokines confirmed previous reports that IL-4, but not IL-25, induced expression of the alternatively activated macrophage marker RELM-α ([@bib51]). However, when combined in vitro, we found a very marked synergy between IL-4 and IL-25 for increased macrophage RELM-α ([Figure 5G,H](#fig5){ref-type="fig"}), as well as Arginase-1 expression ([Figure 5I,J](#fig5){ref-type="fig"}); in each case far above that observed for either cytokine alone.

![IL-25 drives alternative activation and IL-13 expression of macrophages.\
*H. polygyrus*-infected C57BL/6 mice were given 0.4 μg recombinant IL-25 i.p. at day 14--17 (late) post-infection. At day 18 post-infection, PL cells were taken and stimulated with 10 μg Brefeldin A to determine the expression intensity (geomean) of IL-13 (**A**) or were unstimulated to determine the expression intensity (geomean) of RELM-α (**B, C**) within Siglec-F^--^CD11b^+^F4/80^+^ monocytes by flow cytometry, as shown by the example flow cytometry plots in B and compared to fluorescence minus one (FMO) samples stained from the Hp:IL-25 group. Total Siglec-F^+^CD11b^+^ eosinophil (**D**) numbers were calculated from populations shown in the example flow cytometry plots (**E**), numbers of Siglec-F^--^CD11b^+^ (**F**) monocytes. Bone marrow-derived macrophages from C57BL/6 mice were generated in vitro and stimulated with 10 ng/ml IL-4, 200 ng/ml IL-25 or a combination of both for 16 hr before analysis of the percentage of RELM-α expression (**G, H**) and the mean fluorescence intensity (geometric mean) of Arginase-1 expression (**I, J**) within CD11b^+^F4/80^+^ cells by flow cytometry. Results shown are one representative of 2 experiments with n = 4 mice/group (**A--F, I, J**) or pooled from two experiments with n = 4 replicates/group (**G, H**). Data were analysed by unpaired *t* test, where \*=p≤0.05,\*\*=p≤0.01,\*\*\*=p≤0.001 and ns = not significant. Error bars represent Standard Error of the Mean.](elife-38269-fig5){#fig5}

IL-25R co-operates with IL-4Rα signaling to prime innate immunity for effective clearance of *H. polygyrus* {#s2-6}
-----------------------------------------------------------------------------------------------------------

It has long been known that IL-4Rα-mediated signaling is the pivotal component of the protective immune response to helminth infection, being required to generate the appropriate innate and adaptive type two cellular responses. To test whether IL-25-mediated promotion of immunity to primary *H. polygyrus* infection was entirely dependent upon IL-4Rα, or could mediate an IL-4Rα-independent mode of protection, we administered exogenous IL-25 from days 14--17 of infection to *Il4ra*-deficient mice ([Figure 6A](#fig6){ref-type="fig"}). Although late IL-25 injection was previously demonstrated to induce adult worm expulsion in C57BL/6 mice ([Figure 4D](#fig4){ref-type="fig"}), the worm burden of *Il4ra*^-/-^ mice was unaffected by administration of IL-25 at this time-point ([Figure 6B](#fig6){ref-type="fig"}). In a similar manner to C57BL/6 mice ([Figure 5C and D](#fig5){ref-type="fig"}) IL-25 injection significantly increased the percentage of eosinophils in the PL of *H. polygyrus* infected BALB/c mice by day 18 ([Figure 6C](#fig6){ref-type="fig"}). Within the BALB/c strain, 100% of macrophages within the PL expressed RELM-α^+^ by day 18 in *H. polygyrus* infected mice following administration of IL-25 or PBS control, compared to an average of 28% in naïve mice (**[Figure 6D](#fig6){ref-type="fig"}).** However, these responses were completely lacking in infected *Il4ra*^--/--^ mice treated with IL-25 ([Figure 6C,D](#fig6){ref-type="fig"}), confirming that the IL-25 induced response is itself wholly dependent on IL-4Rα signaling.

![IL-4Rα expression is required for activation of the immune system by IL-25.\
*H. polygyru*s-infected *Il4ra*^-/-^ mice (IL-4R^-/-^) were given 0.4 μg recombinant IL-25 i.p. days 14--17 (late) post-infection (**A**). Mice were analyzed at day 28 post-infection for intestinal adult worm burden (**B**). *H. polygyrus*-infected BALB/c and *Il4ra*^-/-^ mice (IL-4R^-/-^) were given 0.4 μg recombinant IL-25 i.p. days 14--17 (late) post-infection. Day 18 post-infection, PL cells were taken to determine the percentage of eosinophils (**C**) and percentage of RELM-α expression within Siglec-F^-^CD11b^+^F4/80^+^ macrophages by flow cytometry (**D**). Results shown are one representative of 2 experiments with n ≥ 4 mice/group (**A--D**). Data were analysed by unpaired *t* test, where \*=p≤0.05,\*\*=p≤0.01,\*\*\*=p≤0.001 and ns = not significant. Error bars represent Standard Error of the Mean.](elife-38269-fig6){#fig6}

Discussion {#s3}
==========

Generation of the type 2 immune response, and protection from helminth parasite infection, requires sustained interaction and participation of both innate and adaptive immune cells ([@bib1]; [@bib19]; [@bib23]; [@bib64]). Alarmins such as IL-25 are potent activators of type 2 immunity, but as we report here, can play an even more important role in stimulating and mobilising effector mechanisms to expel infection. Specifically, we show that adaptive type 2 responses develop normally in the absence of IL-25R but that eosinophil and macrophage responses are impaired, which is likely to explain compromised helminth expulsion in IL25R-deficient mice.

Notably, by day 28 of *H. polygyrus* infection, the *Il17rb*^--/--^ genotype was unable to reduce adult worm or egg burdens, despite the expression of comparable adaptive Th2 response features such as IL-4 and IL-13 expression in CD4^+^ T cells. A requirement for IL-25/IL-25R signaling to expel *H. polygyrus* has previously been reported in other settings in which Th2 response levels appear unaffected, including both a vaccination model ([@bib25]), and following drug-abbreviated primary infection ([@bib45]). Similarly, it has been reported that the resolution of acute *N. brasiliensis* infection is delayed in *Il25*^--/--^ mice despite sufficient Th2 cell differentiation ([@bib38]). These results therefore suggest that Th2 differentiation can occur independently of IL-25R signaling following helminth infection and reinforce the idea that innate type 2 responses can operate autonomously from adaptive type 2 responses to control parasite expulsion ([@bib56]).

A wide range of cell types respond to IL-25, but we demonstrated by chimera experiments that parasite expulsion requires receptor expression on haematopoietic, rather than non-haematopoietic cells in vivo. As adaptive Th2 responses were comparable in IL-25-deficient and sufficient infected mice, we examined innate populations. In *N. brasiliensis* infections, intestinal tuft cell-derived IL-25 drives parasite expulsion and the activation of ILC2s, in a positive feedback loop mediated by IL-13 ([@bib15]; [@bib66]). However, our data indicate that innate lymphoid cells may not be required for immunity to *H. polygyrus*, because anti-CD90 (Thy1) antibody depletion of these cells from *Rag1*-deficient mice did not affect the ability of IL-25 (in combination with IL-4Rα signaling) to expel *H. polygyrus* parasites. Through the use of ST2 staining we were able to demonstrate that both the resident Lin^-^ST2^+^CD90^hi^, and the inflammatory Lin^-^ST2^-^CD90^low^ ILC populations recently described ([@bib26]) are depleted following administration of anti-CD90.2 antibody to *H. polygyrus*-infected mice given IL-25. It is possible that our regime of anti-CD90.2 antibody treatment spares a residual and essential ILC population, but genetic strategies to fully ablate ILCs by deletion of the common gamma chain receptor (γc) are confounded in our system because γc also forms part of the IL-4R.

It has previously been noted that ILC2 numbers show only modest expansion in the MLN of C57BL/6 mice infected with *H. polygyrus* and these can be considerably boosted following administration of IL-25 ([@bib24]). In confirming this, our data also show an increase in total ILCs with *H. polygyrus* infection, of which only a small proportion are ILC2s. One explanation is that chronic *H. polygyrus* infection limits IL-25 and ILC2 expansion by eliciting the production of IL-1β ([@bib70]). We have also demonstrated that *H. polygyrus* infection results in the preferential trafficking of LTi-like ILC3s to the MLN ([@bib35]), pointing again to a diminished role of ILC2s in immunity to this infection, while a recent study reported only modest reduction in adult *H. polygyrus* worm burdens in mice in whom ILC2 numbers were expanded fivefold with IL-2:anti-IL-2 complex ([@bib46]).

In contrast, we uncover striking IL-25R-dependent modifications to macrophage and eosinophil populations following *H. polygyrus* infection, in two important respects. Firstly, the expansion of eosinophil and alternatively activated macrophage numbers seen following helminth infection is strongly amplified by IL-25. Secondly, IL-25 was required for the expression of IL-13 within macrophages, in accordance with earlier publications ([@bib14]; [@bib69]). Macrophages may thus represent a major source of IL-13 in infected animals, suggesting an element of autologous stimulation through the IL-13-responsive IL-4Rα, which is required for macrophage alternative activation.

The alternative activation of macrophages is critical for immunity to *H. polygyrus ([@bib4])*, and we now show that IL-25, in addition to IL-4Rα signaling, is required both for optimal macrophage activation, and for parasite elimination. Thus, for example, the two cytokines synergise dramatically to induce high levels of RELM-α. Consistent with established findings, macrophage activation by IL-25 cannot occur in the absence of IL-4Rα signaling ([@bib31]). Interestingly, the production of IL-25 following nematode infection is itself dependent on IL-4Rα, mediated by IL-13 activation of STAT6 ([@bib71]). Furthermore, upregulation of the IL-25 receptor *Il17rb* in the small intestine is STAT-6 dependent ([@bib71]). We are currently investigating whether macrophage expression of the IL-25 receptor is specifically required for parasite expulsion in the presence of IL-4Rα signaling.

In summary, we demonstrate that the IL-25R is not required for generation of a sufficient Th2 response to helminth infection and that instead, it is required for late effector responses to fully resolve chronic infection. We identify the macrophage and the eosinophil as two prominent populations activated following IL-25 administration, with induction of IL-13 expression within macrophages that is likely, in turn, to drive the suite of intestinal epithelial mechanisms that lead to nematode expulsion ([@bib9]; [@bib36]; [@bib44]). We also clearly demonstrate an enhancement in macrophage alternative activation, which plays a critical role in nematode immobilisation and killing ([@bib25]) and suggest that ILC2s may be redundant in driving IL-25R-dependent immunity to chronic helminth infection. These results now place IL-25 in the central role of mobilising innate effector cells other than ILCs, in the context of an IL-4/13-replete environment, to protect against chronic gastrointestinal helminth infection. Future work will elucidate in greater detail the range of responsive cells and their inter-relationship in the network that orchestrates parasite expulsion and immunity.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\         Designation                   Source or reference                         Identifiers
  (species) or\                                                                                   
  resource                                                                                        
  --------------------- ----------------------------- ------------------------------------------- ------------------------------------
  Mus musculus,\        *Il17rb*^-/-^ (IL-25R^-/-^)   [@bib40]\                                   
  BALB/c                                              Nuocytes represent a new innate\            
                                                      effector leukocyte that mediates\           
                                                      type-2 immunity. Nature\                    
                                                      464:1367--1370                              

  Mus musculus,\        *Rag1*^-/-^                   Mombaerts,P., Iacomini,J.,\                 
  C57BL/6                                             Johnson, R.S., Herrup, K.,\                 
                                                      Tonegawa,S., and Papaioannou, V. E.\        
                                                      1992. Cell. Vol 68: 869--877.\              
                                                      PMID: 1547488                               

  Mus musculus,\        *Il4ra*-/-                    Noben-Trauth N, Shultz LD,\                 
  C57BL/6                                             Brombacher F, Urban\                        
                                                      JF, Jr., Gu H, Paul WE. 1997.\              
                                                      An interleukin 4 (IL-4)-independent\        
                                                      pathway for CD4 + T cell IL-4 production\   
                                                      is revealed in IL-4 receptor-deficient\     
                                                      mice. Proc Natl Acad Sci\                   
                                                      USA 94:10838--10843.                        

  Parasite              *Heligmosomoides*\            [@bib30].\                                  
                        *polygyrus bakeri*            Cultivation of Heligmosomoides\             
                                                      polygyrus: an immunomodulatory\             
                                                      nematode parasite and its\                  
                                                      secreted products. Journal\                 
                                                      of Visualized Experiments\                  
                                                      98:e52412.                                  

  Antibody              Anti-IL-4                     BioXCell                                    Clone 11B11

  Antibody              Anti-IL-13                    BioLegend                                   JES10-5A2

  Antibody              Anti-CD90.2                   BioXCell                                    30H12

  Antibody              Anti-SiglecF                  BD Pharmingen                               E50-2440

  Antibody              Anti-CD11b                    BioLegend                                   M1/70

  Antibody              Anti-F4/80                    BioLegend                                   BM8

  Antibody              Anti-Ly6G                     BioLegend                                   1A8

  Antibody              Anti-Ly6C                     BioLegend                                   AL-21

  Antibody              Anti-RELMα                    R and D Systems                             22603

  Antibody              Anti-Arginase-1\              R and D Systems                             IC5868P
                        (Polyclonal)                                                              

  Antibody              Anti-Lineage                  BioLegend                                   17A2,RB6-8C5,RA3-6B2,Ter-119,M1/70

  Peptide,\             IL-4                          Peprotech                                   214--14
  recombinant protein                                                                             

  Peptide,\             IL-25                         BioLegend                                   587302
  recombinant protein                                                                             

  Commercial\           Foxp3 Staining Kit            eBioScience                                 88--8118
  assay or kit                                                                                    

  Other                 Control IgG2b\                BioXcell                                    LTF-2
                        immunoglobulin                                                            

  Other                 Anti-CD90.2\                  Miltenyi                                    130-049-101
                        Microbeads                                                                
  ------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

BALB/c, IL-25R^--/--^ (*Il17rb*^--/--^) ([@bib40]), C57BL/6, *Rag1*^-/-^ mice and *Il4ra*^-/-^ mice were bred at the University of Edinburgh. All animal protocols adhered to the guidelines of the UK home office, complied with the Animals (Scientific Procedures) Act 1986, were approved by the Ethical Review Committees of the University of Edinburgh and the University of Glasgow, and were performed under the authority of the UK Home Office Project numbers 60/4105 and 70/8384.

Construction of bone marrow chimeras {#s4-2}
------------------------------------

BALB/c or *Il17rb*^--/--^ mice were exposed to 11.5 Gy γ radiation administered in two doses before intravenous reconstitution with 2 million bone marrow cells from BALB/c or *Il17rb*^--/--^ mice, which had been depleted of CD90^+^ cells using CD90.2 microbeads (Miltenyi). Eight weeks post-transfer, recipients were infected with 200 *H. polygyrus* by gavage.

Parasites and antigens {#s4-3}
----------------------

*H. polygyrus bakeri* was maintained and adult *H. polygyrus* E/S (HES) was prepared as described elsewhere ([@bib16]; [@bib30]). Egg counts from individual mice were assessed by weighing the feces before dissolving in 2 ml saturated sodium chloride solution; egg counts were performed using a McMaster chamber and the average number of eggs/g feces calculated per sample. Mice were infected with 200 L3 stage *H. polygyrus* by gavage.

Preparation and administration of IL-4/anti-IL-4 complexes {#s4-4}
----------------------------------------------------------

A pre-prepared complex of 5 μg rIL-4 (Peprotech) and 25 μg anti-IL-4 (clone 11B11; BioXcell, NH) was administered to mice i.p. ([@bib62]).

Depletion of ILCs {#s4-5}
-----------------

*Rag1*^-/-^ mice received 200 μg anti-CD90.2/Thy1.2 (clone 30H12; BioXcell) or a rat IgG2b control (clone LTF-2; BioXcell) i.p. on days 12, 15, 18 and 21 post-infection.

In vitro Ag-specific restimulation {#s4-6}
----------------------------------

A single cell suspension was made of MLN before plating cells at 5 × 10^5^/well in the presence of 2 μg/ml HES and media alone for 72 hr at 37°C/5% CO~2~. Supernatants were then harvested and analysed for IL-4, IL-5, IL-13 by commercially available ELISA (BD Pharmingen).

Generation of bone marrow-derived macrophages {#s4-7}
---------------------------------------------

Bone marrow was extracted from tibia and femurs of C57BL/6 mice. A single cell suspension was formed in 10 ml of PBS by passing through a 23 g needle, then filtered through a 100 µm nylon cell strainer. Cells were plated at a density of 6 × 10^6^ cells/ plate on 90 cm Petri dishes in 10 ml cDMEM with 20% L929 media as a source of M-CSF and incubated at 37°C incubator with 5% CO~2~. A further 5 ml of cDMEM with 20% L929 was added on day 3. Differentiated macrophages were harvested on day 7 using 3 mM EDTA/10 mM glucose in PBS. Cells were washed in PBS, resuspended in cDMEM, plated at 2 × 10^5^ cells/ well in 96 well plates and stimulated with 10 ng/ml IL-4, 200 ng/ml IL-25 or a combination of both for 16 hr before analysis of the cells by flow cytometry.

Flow cytometry {#s4-8}
--------------

All flow cytometry was performed using Becton-Dickinson Canto or LSR-II flow cytometers. For innate cell surface phenotyping, PL or MLN were stained with a combination of antibodies to Siglec-F (E50-2440), CD11b (M1/70), F4/80 (BM8), Ly6G (1A8) and Ly6C (AL-21 or HK1.4). Following fixation and permeabilisation with the Foxp3 staining kit (eBioscience) cells underwent intracellular staining with RELM-α (RnD Systems) followed by zenon anti-rabbit A647 (Invitrogen) and FITC-conjugated anti-human Ki67 (BD Biosciences). For intracellular cytokine staining of monocytes, 0.5−1 × 10^6^ PL cells were incubated with 10 μg/ml Brefeldin A for 4 hr. Following cell surface staining as above, and fixation and permeabilization with Fix/Perm buffer (BD Pharmingen), cells underwent intracellular staining with anti-IL-13 (JES10-5A2). For intracellular staining of lymphocytes, MLNCs were incubated with 0.5 μg/ml PMA and 1 μg/ml ionomycin for 1 hr before the addition of 10 μg/ml Brefeldin A for a further 3 hr. Staining was performed by re-suspending cells in a combination of Abs to CD4 (GK1.5), ICOS (DX29), and the following combination to define Lin^--^: CD3 (17A2), CD5 (53--7.3), CD8α (RPA-T8), CD49b (DX5), CD11c (HL3), F4/80 (BM8), CD19 (eBio1D3), Gr-1 (RB6-8C5), TCRβ (H57-597) and CD11b (M1/70).

Statistical analysis {#s4-9}
--------------------

Data were assessed for normality and equal variance and were log transformed if required; all data passed these criteria and an unpaired *t* test was used or, where more that three groups were tested, a parametric one-way ANOVA followed by Tukey's multiple comparison test was used.
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Decision letter

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Concerted IL-25R and IL-4Rα signaling drive innate type 2 effector immunity and helminth expulsion independently of ILCs\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Andrew J MacPherson as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Tadatsugu Taniguchi as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The paper shows that IL-25 stimulates late clearance of the helminth *Heligmosomoides polygyrus* in synergy with IL-4. These results have been obtained in a series of timed cytokine/cytokine complex supplementation experiments, including in the context of IL-4R deficient strain combinations, using radiation chimeras to show that IL-25R is required on hematogenous cells. A depletion approach was used to show that innate lymphoid cells in RAG mice are not required for the phenotype.

The work is discussed in the context of different helminths and the context of different IL-25-responsive cell types. Data in the paper shows activation of (alternatively activated) macrophages and eosinophils with IL-13 expression as an effector cytokine.

The reviewers were generally positive about the paper and its conclusions. The data regarding the role of IL-4 and IL-25 were considered interesting although both cytokines have been shown before to play a role in parasite resistance. The novelty was considered to be that the immune effector cell is an innate cell and that it does not belong to the group of innate lymphoid cells (ILC). The key experiment to determine this is the case was using an antibody to CD90 to remove innate lymphoid cells in vivo. This approach, however, was considered generally not to be a definitive approach to defining whether ILC are involved or not. The data presented does show that there are changes in the spleen and peritoneum after anti-CD90 antibody treatment of infected mice but this does not mean that this is effective at the sites related to intestinal infection i.e. the gut tissue itself or mesenteric lymph node. Moreover, the authors refer to a paper by Huang et at, 2015 stating that inflammatory ILC2 (and the likely ILC involved) express high levels of CD90 and therefore would be removed by such treatment. In fact the ILC2 were shown to express low levels of CD90 as compared to natural ILC2 and as such are unlikely to be efficiently cleared by anti-CD90 treatment. Thus the current conclusions made that it is a non ILC population of innate cells that are responsible for the protection observed may be premature. This could be tested in either background strain comparing responses in RAG null mice with RAG cγ chain null mice together with appropriate treatments. In fact, Figure 4H is supportive of IL-25 up-regulating ILC2 and this correlates with protection so these experiments will be key to addressing the main conclusions of the paper.

Essential revisions:

The key point would be to convincingly show that the cells that mediate the changes are not an ILC population -- since this is a critical part of the paper and its conclusions. Ideally this should be by experiments in vivo together with better phenotyping of the population. An alternative would be to change the title and the major conclusion of the paper -- and accept that the effects seen could be ILC2 mediated. This would however reduce the conceptual advance that you are proposing.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for sending your revised article entitled \"Concerted IL-25R and IL-4Rα signaling drive innate type 2 effector immunity for optimal helminth expulsion independently of innate lymphoid cells.\" for peer review at *eLife*. Your article has been re-evaluated by a Reviewing Editor, and the evaluation is being overseen by Tadatsugu Taniguchi as the Senior Editor.

In our original decision requesting a revision we stated that the key point would be to convincingly show that the cells that mediate the changes are not an ILC population -- since this is a critical part of the paper and its conclusions. Ideally this should be by experiments in vivo together with better phenotyping of the population. An alternative would be to change the title and the major conclusion of the paper -- and accept that the effects seen could be ILC2 mediated. This would however reduce the conceptual advance that you are proposing.

In the evaluation of the revision we have the following concerns. Other publications have been leveraged to substantiate the claim that anti-CD90.2 treatment will clear all ILC2. The experimental protocols in the cited papers are not the same as were used here and the steady state data may not apply here to the critical groups. Also the data in Figure 3 shows that whilst antibody treatment does significantly reduce levels of ILC there are still ILC remaining. Data is presented from the peritoneum and spleen not the site of parasite infection which is the intestine. It is stated that you did not look in the intestinal tissue as it was needed it for parasite enumeration. This is understood although it is felt that the experiment still needs to be undertaken to support your hypothesis together with experiments in RAGcgamma chain deficient mice to prove ILC have no role. Whilst the results from these extra experiments may well show that the current conclusions are correct i.e. independent of ILC, but the current data was not thought definitive on this point, and without the data from the extra experiments, the present data was considered suggestive but not sufficiently conclusive to justify the current strength of the title and the interpretations.

10.7554/eLife.38269.011

Author response

> \[...\] The reviewers were generally positive about the paper and its conclusions. The data regarding the role of IL-4 and IL-25 were considered interesting although both cytokines have been shown before to play a role in parasite resistance. The novelty was considered to be that the immune effector cell is an innate cell and that it does not belong to the group of innate lymphoid cells (ILC). The key experiment to determine this is the case was using an antibody to CD90 to remove innate lymphoid cells in vivo. This approach, however, was considered generally not to be a definitive approach to defining whether ILC are involved or not. The data presented does show that there are changes in the spleen and peritoneum after anti-CD90 antibody treatment of infected mice but this does not mean that this is effective at the sites related to intestinal infection i.e. the gut tissue itself or mesenteric lymph node. Moreover, the authors refer to a paper by Huang et at, 2015 stating that inflammatory ILC2 (and the likely ILC involved) express high levels of CD90 and therefore would be removed by such treatment. In fact the ILC2 were shown to express low levels of CD90 as compared to natural ILC2 and as such are unlikely to be efficiently cleared by anti-CD90 treatment. Thus the current conclusions made that it is a non ILC population of innate cells that are responsible for the protection observed may be premature. This could be tested in either background strain comparing responses in RAG null mice with RAG cγ chain null mice together with appropriate treatments. In fact, Figure 4H is supportive of IL-25 up-regulating ILC2 and this correlates with protection so these experiments will be key to addressing the main conclusions of the paper.

Regarding the first issue, of whether gut tissue ILCs are equally depleted, we would refer to published studies in which anti-CD90 depletion removes ILCs within both the intestine and mLN (Sonnenberg et al., 2012 Science 336:1321-1325), and to emphasise that our protocol delivering anti-CD90.2 at days 12, 15, 18 and 21 post-infection should mediate efficient removal of all resident ILCs within the lymphoid and intestinal tissue, particularly as all resident ILCs are reported to express high levels of CD90 at steady state (Kim et al., 2015 Immunity 43:107; Hepworth et al., 2013 Nature 498:113-117).

We could not directly evaluate intestinal tissue populations as this tissue was used to evaluate parasite burdens. In addition, the lymph nodes of RAG mice used in these experiments are small and lymphopenic (Seymour et al., 2006 Vet Path 43:401-423) and could not be reliably analysed by flow cytometry.

On the second question of iILC2 expression of CD90/Thy1, we accept that our wording in the Discussion of the manuscript was imprecise; Huang et al., 2015, describes two populations of ILC that are induced in response to alarmin administration, IL-25 responsive Lin^-^IL-7Ra^+^Thy1^low^ST2-KLRG1^hi^ iILC2s; and resident and IL-33 responsive Lin^-^IL-7Ra^+^Thy1^hi^ST2+KLRG1^int^ nILC2s. We now modify our text in the third paragraph of the Discussion in order to clarify this point.

In our gating strategy for Figure 3, cells from RAGKO mice were stained for lineage (CD3, CD5, CD8a, CD11c, CD19, DX5, F4/80, GR-1), TCRβ and CD11b, CD45, ICOS, ST2 and CD4, allowing us to gate on all lineage negative populations and distinguish ST2^+^ (nILC2) from ST2^-^ (iILC) subsets. Using this gating strategy, we find that all populations are depleted following administration of anti-CD90.2 in both the spleen and peritoneal lavage. We now include these data in Figure 3 (Panels E, F, G) and state this in the last paragraph of the subsection "Effective clearance of adult worms in immune-deficient mice requires IL-25R and IL-4Rα signaling through the innate immune compartment, but acts independently of ILCs" and in the third paragraph of the Discussion.

> Essential revisions:
>
> The key point would be to convincingly show that the cells that mediate the changes are not an ILC population -- since this is a critical part of the paper and its conclusions. Ideally this should be by experiments in vivo together with better phenotyping of the population. An alternative would be to change the title and the major conclusion of the paper -- and accept that the effects seen could be ILC2 mediated. This would however reduce the conceptual advance that you are proposing.

We address this concern above, by clarifying our statement referring to Huang et al., 2015 in the third paragraph of the Discussion, and including the data demonstrating that the antibody depletion approach efficiently removed all ILC subsets from our mice. As these mice remained able to expel parasites, we feel that the title and conclusion of the paper remain valid.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> \[...\] In the evaluation of the revision we have the following concerns. Other publications have been leveraged to substantiate the claim that anti-CD90.2 treatment will clear all ILC2. The experimental protocols in the cited papers are not the same as were used here and the steady state data may not apply here to the critical groups. Also the data in Figure 3 shows that whilst antibody treatment does significantly reduce levels of ILC there are still ILC remaining. Data is presented from the peritoneum and spleen not the site of parasite infection which is the intestine. It is stated that you did not look in the intestinal tissue as it was needed it for parasite enumeration. This is understood although it is felt that the experiment still needs to be undertaken to support your hypothesis together with experiments in RAGcgamma chain deficient mice to prove ILC have no role. Whilst the results from these extra experiments may well show that the current conclusions are correct i.e. independent of ILC, but the current data was not thought definitive on this point, and without the data from the extra experiments, the present data was considered suggestive but not sufficiently conclusive to justify the current strength of the title and the interpretations.

We are again grateful to the editors and reviewers for their constructive criticism and final positive evaluation. We have amended the text as follows to remove any categorical statements about the role of ILC2s, in concordance with the above advice:

· Title: removed \"independently of innate lymphoid cells\"

· Abstract: amended the final two sentences to avoid claiming ILCs are totally absent

· Results: deleted *\"*but acts independently of ILCs\"

· Results: inserted reference to Pelly et al. who showed ILC2 transfer was ineffective

· Discussion: amended the sentence stating \"we were able to exclude innate lymphoid cells\" to a more reserved \"our data indicate that ILCs may not be required\"

· Discussion: inserted new sentence acknowledging the shortcoming of anti-CD90 antibody treatment and discussing the problem with γc deficient mice in our system

· Discussion: added reference to the Pelly et al. paper

· Discussion: replaced \"establish that ILC2s are redundant\" with \"suggest that ILC2s may be redundant\"

· Figure 3 Legend: removed \"independently of ILCs\"
